164
Participants
Start Date
September 30, 2007
Primary Completion Date
January 31, 2013
Study Completion Date
July 31, 2013
carfilzomib
Intravenous (IV) injection over 2 to 10 minutes twice weekly for three weeks followed by 12 days of rest.
St. Vincent's Comprehensive Cancer Center, New York
Oncology & Hematology Assoc. of W. Broward, Tamarac
H. Lee Moffitt Cancer Center & Research Institute, Tampa
Jackson Oncology Associates, Jackson
Hattiesburg Clinic, Hattiesburg
Montgomery Cancer Center, Mount Sterling
Cleveland Clinic, Cleveland
Summa Health System, Akron
Gabrail Cancer Center, Canton
Signal Point Clinical Research Center, LLC, Middletown
Dayton Clinical Oncology Program, Dayton
Mayo Clinic Rochester, Rochester
Orchard Research, Skokie
Northwestern University, Chicago
Washington University School of Medicine, St Louis
MD Anderson Cancer Center, Houston
Texas Oncology Cancer Center, Austin
Harrington Cancer Center, Amarillo
Rocky Mountain Blood and Marrow Transplant Program, Denver
Mayo Clinic Scottsdale, Scottsdale
Tower Cancer Research Foundation, Beverly Hills
Therapeutic Research Institute of Orange County, Laguna Hills
Emory University Winship Cancer Institute, Atlanta
University of Kentucky College of Medicine, Lexington
University of Michigan Comprehensive Cancer Center, Ann Arbor
Hackensack University Medical Center, Hackensack
University of Calgary, Calgary
University of Alberta Cross Cancer Institute, Edmonton
University of Toronto Princess Margaret Hospital, Toronto
Royal Victoria Hospital, Montreal
Lead Sponsor
Amgen
INDUSTRY